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Abstract
Background: The DRAGON score, which includes clinical and computed
tomographic (CT) scan parameters, predicts functional outcomes in ischemic
stroke patients treated with intravenous tissue plasminogen activator (IV tPA).
We assessed the utility of the DRAGON score in predicting functional outcome in
stroke patients receiving both IV tPA and endovascular therapy.
Methods: A retrospective chart review of patients treated at our institution from
February 2009 to October 2015 was conducted. All patients with computed
tomography angiography (CTA) proven large vessel occlusions (LVO) who
underwent intravenous thrombolysis and endovascular therapy were included.
Baseline DRAGON scores and modified Rankin Score (mRS) at the time of hospital
discharge was calculated. Good outcome was defined as mRS ≤3.
Results: Fifty‑eight patients with LVO of the anterior circulation were studied. The
mean DRAGON score of patients on admission was 5.3 (range, 3–8). All patients
received IV tPA and endovascular therapy. Multivariate analysis demonstrated
that DRAGON scores ≥7 was associated with higher mRS (P < 0.006) and higher
mortality (P < 0.0001) compared with DRAGON scores ≤6. Patients with DRAGON
scores of 7 and 8 on admission had a mortality rate of 3.8% and 40%, respectively.
Conclusions: The DRAGON score can help predict better functional outcomes in
ischemic stroke patients receiving both IV tPA and endovascular therapy. This data
supports the use of the DRAGON score in selecting patients who could potentially
benefit from more invasive therapies such as endovascular treatment. Larger
prospective studies are warranted to further validate these results.

Access this article online
Website:
www.surgicalneurologyint.com
DOI:
10.4103/2152-7806.210993
Quick Response Code:

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and
build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
For reprints contact: reprints@medknow.com
How to cite this article: Wang A, Pednekar N, Lehrer R, Todo A, Sahni R, Marks S, et al. DRAGON score predicts functional outcomes in acute ischemic stroke patients
receiving both intravenous tissue plasminogen activator and endovascular therapy. Surg Neurol Int 2017;8:149.
http://surgicalneurologyint.com/DRAGON-score-predicts-functional-outcomes-in-acute-ischemic-stroke-patients-receiving-both-intravenous-tissue-plasminogen-activator-andendovascular-therapy/

© 2017 Surgical Neurology International | Published by Wolters Kluwer - Medknow

Surgical Neurology International 2017, 8:149

http://www.surgicalneurologyint.com/content/8/1/149

Key Words: Endovascular thrombectomy, ischemic stroke, large vessel occlusion,
tissue plasminogen activator

INTRODUCTION
Intravenous tissue plasminogen activator (IV tPA) has
been shown to improve functional outcomes in patients
with acute ischemic strokes secondary to large vessel
occlusions (LVO).[6] Despite this, IV tPA has a low rate of
recanalization, and patients with LVO can further benefit
from endovascular therapy.[3] To this end, the DRAGON
score was designed to prognosticate patient outcomes
after IV tPA therapy, as well as to identify patients who
could benefit from further endovascular treatment.[4,12]
The DRAGON score is a 10‑point scoring system
based on computed tomography (CT) findings of
hypoDensity or a dense MCA sign, prestroke modified
Rankin Scale (mRS), Age, Glucose level on admission,
Onset‑to‑treatment time, and initial National Institutes
of Health Stroke Score (NIHSS).[12] The score has shown
good performance in predicting poor patient outcomes
despite administration of IV tPA.[13]

aspiration via a large‑bore (≥5 Fr) intracranial reperfusion
catheter. The degree of recanalization (Thrombolysis in
Cerebral Infarction, TICI score) was determined at the
end of the case by an endovascular surgeon.
The primary clinical outcome was the modified Rankin Scale
(mRS) score at discharge. All mRS scores were reported
on physical therapy progress notes and reviewed by stroke
neurologists. Good outcome was defined as a mRS score 0–3
and poor outcome as mRS 4–6 (death or dependency).
Univariate analysis for predictors of outcome were
determined using the 2 and Student’s t‑test. Means
were compared using the Student’s t‑test (two‑tailed),
and percentages were compared using the 2 test.
P values ≤0.05 were considered significant. Statistical
analysis was performed using NCSS Statistical Software
Inc V10.0 (Salt Lake City, Utah).

RESULTS

Recent randomized clinical trials using modern
endovascular techniques have demonstrated the efficacy
of endovascular stroke therapy for treating patients with
acute ischemic strokes from LVO.[1,7,11] At present, there is
no data to suggest that the DRAGON score can predict
functional outcome in stroke patients receiving both IV
tPA and endovascular therapy. We sought to assess the
utility of the DRAGON score in predicting functional
outcome in anterior circulation stroke patients receiving
both IV tPA and endovascular therapy.

During the study period, a total of 58 patients met the
inclusion criteria [Table 2]. The mean patient age was
61.4 years, and the mean National Institutes of Health
Stroke Scale (NIHSS) score was 15.6 (range 6–36). In our
study population, there were no patients with a DRAGON
score of 0–2 and 9–10. There was no significant difference
in age or NIHSS between patients with good clinical
outcomes (mRS ≤3) and those with poor clinical outcomes
(mRS ≥4). Pretreatment DRAGON scores and percentage
of good outcomes at discharge are shown in Table 3.

MATERIALS AND METHODS

Table 1: The DRAGON score

Institutional Review Board approval was obtained prior
to study initiation. A retrospective chart review was
conducted among anterior circulation ischemic stroke
patients treated with IV tPA and endovascular therapy, with
either the ADAPT technique or stent‑triever. The major
inclusion criteria were anterior circulation LVO seen on
computed tomography angiography (CTA) and age ≥18.
Anterior circulation LVO was defined as occlusions of the
internal carotid artery (ICA) and M1 and/or M2 segment
of the middle cerebral artery (MCA). Baseline DRAGON
scores [Table 1], details of the treatment, and clinical
outcome at time of hospital discharge were determined.
All endovascular interventions were performed on a flat
detector‑based biplane angiographic system under general
anesthesia. Endovascular treatment included mechanical
thrombectomy with or without intraarterial thrombolysis
(intraarterial tissue plasminogen activator). Mechanical
thrombectomy was defined as a stentriever and/or direct

Variable

Category

(Hyper) Dense cerebral artery
sign or early infarct signs on
admission CT head scan

None
Either of them
Both
No
Yes
<65 years
65-79 years
≥80 years
≤8 mmol/L (144 mg/dL)
>8 mmol/L (144 mg/dL)
≤90 min
>90 min
0-4
5-9
10-15
>15

mRS Score >1, prestroke
Age

Glucose level on admission
Onset‑to‑treatment time
NIHSS on admission

Points
0
1
2
0
1
0
1
2
0
1
0
1
0
1
2
3

CT: Computed tomography, mRS: Modified Rankin Score, NIHSS: National Institutes
of Health Stroke Scale
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The highest and lowest percentage of good
outcomes (mRS ≤ 3) was found in patients with a
DRAGON score of 3 and 8, respectively. With increasing
DRAGON scores, worse clinical outcome (mRS ≥ 4)
was observed [Figure 1]. Mortality rates of 3.8% and 40%
were observed in patients with DRAGON scores of 7 and
8, respectively.
The association between subgroups of DRAGON scores
and mRS and mortality rate is shown in Figure 2.
DRAGON scores were grouped into high (score of
7–8), intermediate (score of 5–6), and low (score of
3–4) subgroups. High DRAGON scores were associated
with higher mRS scores (average 4.8 ± 0.3; P < 0.006)
Table 2: Baseline characteristics of patients
Characteristic

All patients
(n=58)

mRS ≤3
(n=33)

mRS ≥4
(n=25)

P

Age, mean (range)
NIHSS, mean (range)
DRAGON Score
0‑2
3
4
5
6
7
8
9‑10

61.4 (32-85)
15.6 (6-36)

57.8
14.1

66.2
17.5

0.018
0.019

0
10 (17%)
7 (12%)
19 (33%)
7 (12%)
10 (17%)
5 (9%)
0

‑
8
4
15
4
2
0
‑

‑
2
3
4
3
8
5
‑

mRS: Modified Rankin Score at discharge, NIHSS: National Institutes of Health Stroke
Scale

Table 3: DRAGON Scores, average mRS at discharge,
and % good outcome of the 58 patients
DRAGON Score
3
4
5
6
7
8

Average mRS

% Good outcome*

2.1
2.3
2.6
2.9
4.8
4.8

80
57
79
57
20
0

compared with intermediate scores (average mRS
2.6 ± 0.4) and low scores (average mRS 2.2 ± 0.5). High
DRAGON scores (7–8) were also associated with higher
mortality (40%; P < 0.0001) compared with intermediate
and low DRAGON scores (3.8% and 0%, respectively).

DISCUSSION
The DRAGON score was originally proposed as an
easy way of identifying patients who should be given
additional therapeutic interventions (i.e., endovascular,
hypothermia) due to poor functional outcomes after
IV tPA.[12] The score takes into account various initial
prognosticating factors (age, initial NIHSS, time from
onset, CT image findings, and blood sugar levels)
and provides relevance based on multivariate logistic
regression. Strbian et al. showed the predicative value of
their scoring system by demonstrating that patients with
DRAGON scores of 8 and 9–10 carried a 70% and 100%
proportion of miserable outcomes (mRS ≥5, bedridden,
incontinent, requiring constant nursing care, or dead),
respectively, compared to patients with lower DRAGON
scores.[4] These patients could be suitable for additional
rescue therapies such as endovascular intervention.
Although the DRAGON score has been validated by
several centers across the world, there are no studies
investigating the utility of the score in predicting
functional outcomes of patients receiving both IV tPA
and endovascular therapy.[2,4,9,13] The results of our study
show that patients with a DRAGON score of 7–8 had
significantly worse clinical outcomes (mRS ≥4) and
higher mortality compared to patients with DRAGON
scores ≤6. This demonstrates that the DRAGON score
can predict patient clinical outcomes after treatment
with IV tPA and endovascular therapy. In addition, the
score can be used to select patients who could benefit
from endovascular intervention.
There exist a few scoring systems in the literature that
have shown promise in predicting the clinical outcome,

mRS: Modified Rankin Score, % Good outcome (defined as mRS ≤3 at time of discharge)

Figure 1: Clinical outcome at discharge according to the DRAGON
score

Figure 2: Correlation between DRAGON score and mRS and
mortality
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and thus, appropriately select patients for endovascular
therapy. The CTA collateral score, based on the degree
of collateral circulation on pretreatment CTA, has been
shown to predict smaller infarct volumes and better
clinical outcomes in patients after recanalization with
endovascular intervention.[5] The Capillary Index Score,
based on a preintervention cerebral angiogram, can
predict favorable outcomes in patients with ischemic
strokes.[8] Similarly, the PRE (Pittsburgh Response to
Endovascular therapy) score, which incorporates age,
admission NIHSS, and ASPECT score on head CT, can
predict outcomes and facilitates selection for patients
who could benefit from endovascular intervention.[10]
Compared with other scoring systems, the DRAGON
score is (1) fast to obtain, (2) consists of parameters
known at admission, and (3) has a low cost; free.[2,4,9,13]
Our study results show that the DRAGON score can in
fact be applied to endovascular patients who have already
received IV tPA.
A few limitations need to be acknowledged in our
current study. First, despite controlling for established
stroke outcome predictors, we cannot rule out
additional baseline confounding variables that can
affect patient outcomes. Second, this study uses data
from only one center. Our aim was to apply an already
established scoring system towards predicting stroke
outcomes rather than investigate a novel prognostic
tool. Third, as we only included anterior circulation
strokes, our study results cannot be applied to posterior
circulation strokes. Further data is needed to determine
if the DRAGON score can be adapted for posterior
circulation strokes.

CONCLUSIONS
The DRAGON score is a fast and easy score to obtain that
can predict the functional outcomes of acute ischemic
stroke patients treated with IV tPA and endovascular
therapy. Larger prospective studies and external validation
of the score as it applies to both IV tPA and endovascular
therapy is warranted.
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